The mild cognitive impairment window for optimal Alzheimer's disease intervention

Kevin Mekulu; Faisal Aqlan; Hui Yang

doi:10.1177/25424823251370768

The mild cognitive impairment window for optimal Alzheimer's disease intervention

Kevin Mekulu
, Faisal Aqlan
, Hui Yang

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

The FDA approval of disease-modifying Alzheimer's disease therapies marks a major shift in treatment but exposes a critical challenge: identifying patients during the mild cognitive impairment (MCI) stage when intervention is most effective. Despite early biological changes, most diagnoses occur after significant decline. Drawing from over 180 stakeholder interviews conducted through the NSF I-Corps program reveal major detection gaps across primary care, specialty access, and available tools. This commentary highlights the consequences of delayed diagnosis and proposes translational strategies to align early detection with therapeutic opportunity, positioning MCI as the critical window for Alzheimer's disease intervention.

Original language	English (US)
Journal	Journal of Alzheimer's Disease Reports
Volume	9
DOIs	https://doi.org/10.1177/25424823251370768
State	Published - Jan 1 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Neuroscience
Clinical Psychology
Geriatrics and Gerontology
Psychiatry and Mental health

Access to Document

10.1177/25424823251370768

Cite this

@article{5459cd5d34cd47b4b43c3917afaee6b3,

title = "The mild cognitive impairment window for optimal Alzheimer's disease intervention",

abstract = "The FDA approval of disease-modifying Alzheimer's disease therapies marks a major shift in treatment but exposes a critical challenge: identifying patients during the mild cognitive impairment (MCI) stage when intervention is most effective. Despite early biological changes, most diagnoses occur after significant decline. Drawing from over 180 stakeholder interviews conducted through the NSF I-Corps program reveal major detection gaps across primary care, specialty access, and available tools. This commentary highlights the consequences of delayed diagnosis and proposes translational strategies to align early detection with therapeutic opportunity, positioning MCI as the critical window for Alzheimer's disease intervention.",

author = "Kevin Mekulu and Faisal Aqlan and Hui Yang",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).",

year = "2025",

month = jan,

day = "1",

doi = "10.1177/25424823251370768",

language = "English (US)",

volume = "9",

journal = "Journal of Alzheimer's Disease Reports",

issn = "2542-4823",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - The mild cognitive impairment window for optimal Alzheimer's disease intervention

AU - Mekulu, Kevin

AU - Aqlan, Faisal

AU - Yang, Hui

N1 - Publisher Copyright: © The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PY - 2025/1/1

Y1 - 2025/1/1

N2 - The FDA approval of disease-modifying Alzheimer's disease therapies marks a major shift in treatment but exposes a critical challenge: identifying patients during the mild cognitive impairment (MCI) stage when intervention is most effective. Despite early biological changes, most diagnoses occur after significant decline. Drawing from over 180 stakeholder interviews conducted through the NSF I-Corps program reveal major detection gaps across primary care, specialty access, and available tools. This commentary highlights the consequences of delayed diagnosis and proposes translational strategies to align early detection with therapeutic opportunity, positioning MCI as the critical window for Alzheimer's disease intervention.

AB - The FDA approval of disease-modifying Alzheimer's disease therapies marks a major shift in treatment but exposes a critical challenge: identifying patients during the mild cognitive impairment (MCI) stage when intervention is most effective. Despite early biological changes, most diagnoses occur after significant decline. Drawing from over 180 stakeholder interviews conducted through the NSF I-Corps program reveal major detection gaps across primary care, specialty access, and available tools. This commentary highlights the consequences of delayed diagnosis and proposes translational strategies to align early detection with therapeutic opportunity, positioning MCI as the critical window for Alzheimer's disease intervention.

UR - https://www.scopus.com/pages/publications/105031050038

UR - https://www.scopus.com/pages/publications/105031050038#tab=citedBy

U2 - 10.1177/25424823251370768

DO - 10.1177/25424823251370768

M3 - Comment/debate

C2 - 40842658

AN - SCOPUS:105031050038

SN - 2542-4823

VL - 9

JO - Journal of Alzheimer's Disease Reports

JF - Journal of Alzheimer's Disease Reports

ER -

The mild cognitive impairment window for optimal Alzheimer's disease intervention

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this